Pharsight

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9561177	February, 2019	Institution Denied	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9629965	February, 2019	Final Written Decision	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9468747	February, 2019	Final Written Decision	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9468747	February, 2019	Institution Denied	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9211253	February, 2019	Institution Denied	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9775838	February, 2019	Institution Denied	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9211253	February, 2019	Final Written Decision	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.
US9629965	February, 2019	Institution Denied	Opiant Pharmaceuticals, Inc.	Nalox-1 Pharmaceuticals, LLC et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629965	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (10 years from now)
US9480644	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (10 years from now)
US10085937	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (10 years from now)
US9707226	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (10 years from now)
US9561177	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (10 years from now)
US9468747	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (10 years from now)
US9211253	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (10 years from now)
US9775838	EMERGENT	Nasal drug products and methods of their use	Mar, 2035 (10 years from now)

Narcan is owned by Emergent.

Narcan contains Naloxone Hydrochloride.

Narcan has a total of 8 drug patents out of which 0 drug patents have expired.

Narcan was authorised for market use on 24 January, 2017.

Narcan is available in spray, metered;nasal dosage forms.

Narcan can be used as use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression..

The generics of Narcan are possible to be released after 16 March, 2035.

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2017

Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

Dosage: SPRAY, METERED;NASAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2 mg/spray	28 Dec, 2017	1		16 Mar, 2035
4 mg/spray	15 Jul, 2016	1	19 Apr, 2019	16 Mar, 2035	Eligible

Strength	Dosage	Availability
4MG/SPRAY	SPRAY, METERED;NASAL	Over the counter
2MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SPRAY, METERED;NASAL	Discontinued

Pharsight

Narcan patents expiration

NARCAN family patents

Related content